BaroFold, Inc. Appoints J. William Freytag, Ph.D. as President and Chief Executive Officer
01/28/2009
BaroFold Inc., Initiates First Human Studies for Multiple Sclerosis Drug Candidate, BaroFeron™
06/16/2008
Julie L. Bernard, J.D. Appointed to Chief Intellectual Property Counsel Position for BaroFold, Inc.
01/21/2008
BaroFold Announces the Successful Completion of Technology Evaluation Agreement
01/04/2008
01/28/2009
BaroFold Inc., Initiates First Human Studies for Multiple Sclerosis Drug Candidate, BaroFeron™
06/16/2008
Julie L. Bernard, J.D. Appointed to Chief Intellectual Property Counsel Position for BaroFold, Inc.
01/21/2008
BaroFold Announces the Successful Completion of Technology Evaluation Agreement
01/04/2008
